LOGIN  |  REGISTER
Cue Biopharma

Qiagen to release results for Q3 2023 and hold webcast

October 09, 2023 | Last Trade: US$44.48 0.00 0.00

Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.)

Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time. 
(For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.)

Three options for joining the conference call

  1. Register for call back connection - Click here: Connect me

Service available 15 minutes before call start 

  1. Dial-in by phone

U.S.: +1 646 828 8193
UK: +44 (0)330 165 3656
GER: +49 (0)69 6610 2491
Conference ID: 4759185
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. 

  1. Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/event_security_fail.html

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to  Insight solutions that enable customers to gain valuable molecular insights from samples containing  the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable  insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB